Mixed lineage leukemias (MLLs) are human histone H3 lysine-4-specific methyl transferases that have critical roles in gene expression, epigenetics and cancer. Herein, we demonstrated that antisense-mediated knockdown of MLL1 induced cell-cycle arrest and apoptosis in cultured cells. Intriguingly, application of MLL1 antisense specifically knocked down MLL1 in vivo and suppressed the growth of xenografted cervical tumor implanted in nude mouse. MLL1 knockdown downregulated various growth and angiogenic factors, such as HIF1a, VEGF and CD31, in tumor tissue affecting tumor growth. MLL1 is overexpressed along the line of vascular network and localized adjacent to endothelial cell layer expressing CD31, indicating potential roles of MLL1 in vasculogenesis. MLL1 is also overexpressed in the hypoxic regions along with HIF1a. Overall, our studies demonstrated that MLL1 is a key factor in hypoxia signaling, vasculogenesis and tumor growth, and its depletion suppresses tumor growth in vivo, indicating its potential in novel cancer therapy.
INTRODUCTION
Understanding the tumor microenvironment and the signaling mechanism that controls tumor growth, angiogenesis and metastasis is critical for developing novel and effective cancer therapy. Abnormal expression of various transcription factors has been implicated in tumorigenesis and they are potential targets for novel cancer therapy. [1] [2] [3] [4] For example, epidermal growth factor receptor and vascular endothelial growth factor (VEGF) receptor, which are overexpressed in variety of cancers, are being targeted for developing cancer therapy. 5, 6 Histone-modifying enzymes that are key factors in gene regulation and epigenetics are found to be misregulated in variety of tumors and therefore provides novel platform for understanding the tumor biology as well as developing potential targeted therapy. [7] [8] [9] [10] [11] Mixed lineage leukemias (MLLs) are human histone H3 lysine-4 (H3K4)-specific methyl transferases (HMTs) that have critical roles in gene expression. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In human, there are several MLL families of proteins that include MLL1, MLL2, MLL3, MLL4, Set1 and so on. MLLs are well known for their association with oncogenic transformation. 13, 18, 25, 26 MLL1 is often rearranged in acute lymphoblastic and myeloid leukemias in children and adults. 13, 18, 25 MLL2-4 are mutated or misregulated in various solid tumors. [27] [28] [29] [30] [31] [32] [33] MLLs are also well known as master regulators of homeobox (HOX) genes that are critical factors during cell differentiation and embryonic development. MLLs (MLL1-4) exist as multi-protein complexes inside cell, with several common subunits that include Ash2, Wdr5, Rbbp5, Dpy30 and CGBP. 26, 34, 35 The distinct cellular functions of different MLLs, as well as their interacting proteins, still remain elusive. Studies from our laboratory and others showed that MLL1 is a key factor in cell-cycle progression and stress response. 21, 26, [36] [37] [38] Depletion of MLL1 results in cell-cycle arrest at G2/M phase. 21, 39 MLLs also participate in steroid hormone-mediated gene regulation and signaling, indicating their potential association with hormone-linked diseases, including breast and prostate cancer. 26, [40] [41] [42] Although a great deal of efforts are being invested towards understanding the functions of MLL histone methylases in gene regulation and disease, their therapeutic potential remains mostly unexplored.
To understand the roles of MLL histone methylases in tumor cell signaling and explore their therapeutic potential, we knocked down MLL1 in different cultured tumor cells and also in mice and examined its impact on cell viability, cell-cycle progression and tumor growth in vivo. Our results demonstrated that MLL1 has critical roles in cell-cycle progression. Importantly, knockdown of MLL1 induced apoptosis in cultured tumor cells and suppressed the growth of xenografted tumor in vivo (xenografted tumor model). MLL1 is also associated with angiogenesis and hypoxia signaling.
RESULTS

MLL1 is essential for cell viability and its depletion induces apoptosis in cultured mammalian cells
To investigate the importance of MLL1 in cell survival and maintenance, we knocked it down in different malignant and nonmalignant cultured human cell lines using MLL1-specific phosphorothioate antisense oligonucleotide and examined its impact on cell viability. Initially, we screened five different MLL1 antisenses (MLL1-A1-MLL1-A5, Supplementary Table S1 , Supplementary Figure S1 ) to examine their knockdown efficacy and specificities in HeLa cells. MLL1-A3 and MLL1-A5 antisenses showed the most effective MLL1 knockdown in comparison with other antisenses examined ( Supplementary Figures S1b-f ). MLL1-A3 showed slightly higher knockdown efficacy than MLL1-A5 ( Supplementary Figures S1b-f ). As MLL1-A3 was the most effective antisense, it was used for all the remaining studies and it is termed as MLL1 antisense throughout this manuscript. To examine the efficacy of the antisenses, we transfected HeLa cells with varying concentrations (3-7 mg) of MLL1-specific and scramble (that has no homology to MLL1) antisenses ( Supplementary Table S1 ) and incubated for 48 h. Our analysis demonstrated that MLL1 antisense efficiently knocked down MLL1 both at the protein and mRNA level (compare lanes 3-5 with lane 1, Figures 1a and b ). The level of MLL2 (control) was mostly unaffected upon MLL1 knockdown (Figures 1a and b ). The scramble antisense had no significant effect on MLL1 expression (lane 2, Figures 1a and b) . These results demonstrated that MLL1 antisense specifically knocked down MLL1 in HeLa cells.
To examine the effects of MLL1 knockdown on cell viability, we transfected the MLL1 antisense (7 mg) to different malignant and nonmalignant cells and then visualized the cell morphology under microscope and also quantified the cell viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figures 1c and d) . The knockdown efficiencies of MLL1 in different cell lines are shown in the Supplementary Figure S2 . Microscopic analysis showed that scramble antisense has no significant effects on cellular morphology and growth in most cell types ( Figure 1c ). The growth and morphology of HeLa, H358 (lung cancer), SW-480 (colon cancer), MCF7 (human breast cancer) and JAR (human placenta choriocarcinoma) cells were severely affected upon MLL1 knockdown ( Figure 1c ). Cells were arrested, rounded up and degenerated. MTT assay showed that HeLa cells were the most sensitive (490% cell death) to MLL1 knockdown ( Figure 1d ). Breast cancer cells (MCF7, 50% cell death) were slightly more sensitive than normal breast cells (MCF10, 22% death) ( Figure 1d ). Lung cancer and placenta choriocarcinoma cells were also killed upon MLL1 knockdown. As HeLa cells were most sensitive towards MLL1 knockdown, we performed all the following experiments using this cell line.
To understand the nature of cell death upon MLL1 knockdown, we performed various apoptosis assays. Terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) assay confirmed that MLL1 knockdown induced apoptosis in HeLa cells ( Figure 1e ). Briefly, cells were transfected with MLL1 antisense for 48 h and then subjected to 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI) staining, end-labeling of the nicked DNA with fluorescent dUTP (TUNEL assay) and propidium iodide (PI) staining. Analysis of DAPI-stained cells showed that MLL1 antisense induced nuclear condensation (intense DAPI staining) and fragmentation of cell nuclei (condensation and fragmentations are shown by arrows, Figure 1e ). Fluorescent dUTP end-labeling demonstrated that cell nuclei were fragmented upon MLL1-antisense treatment (green-colored nuclei in MLL1-antisense-treated cells, dUTP panels in Figure 1e ). PI (another DNA-binding fluorescent dye that stains dead cells) staining demonstrated that all the cells that were stained green in dUTP staining were colocalized with red (dead) cells (PI staining, Figure 1e ). These observations demonstrated that MLL1 knockdown induced apoptosis in HeLa cells. MLL1 knockdown also induced release of cytochrome-c from the mitochondria to cytosol and also induced caspase 3/7 activity (Supplementary Figure S3 ).
We also performed the apoptosis assays (TUNEL and caspase assays) on two nonmalignant cell lines (MCF10 and CCD-18Co) that showed relatively less sensitivity towards MLL1 knockdown (as seen in Figures 1c and d ). TUNEL and caspase analysis showed that MLL1 knockdown induced relatively lesser degree of nuclear fragmentation, caspase 3/7 activation and apoptotic cell death in both MCF10 and CCD-18Co than HeLa cells, indicating higher sensitivity of malignant cells towards MLL1 knockdown (Supplementary Figures S4a-d and Figures 1c and d) .
To rule out the potential off-target effect of MLL1 antisense (MLL1-A3), we examined the impact of MLL1 knockdown using another MLL1 antisense (MLL1-A5, Supplementary Table S1 ) on cell viability. Our analysis showed that transfection with MLL1-A5 also effectively knocked down MLL1 level in HeLa cells without affecting MLL2 expression (Supplementary Figure S5a MLL1 is a critical factor in cell-cycle progression As MLL1 showed essential roles in cell viability, we examined its potential mode of action. We knocked down MLL1 in HeLa cells using specific antisense oligonucleotide and analyzed its impact on cell-cycle progression. We transfected HeLa cells with MLL1 or scramble antisense for varying time periods, stained with PI and analyzed by flow cytometry. Upon application of the MLL1 antisense, even at 48 h post treatment, the cell population at G0/G1 phase was decreased dramatically from 72.5 to 40.3%, whereas G2/M-phase cell population was increased from 13.6 to 35.1%, indicating potential cell-cycle arrest at G2/M phase. At 24 h post antisense treatment, 24% cells underwent apoptosis (Figure 2a ). Longer time incubation with MLL1 antisense increased apoptotic cell population (61% at 72 h), whereas cell populations at G0/G1 and G2/M phases were decreased (Figure 2a ). Scramble antisense showed no significant impact on cell-cycle progression. These results demonstrated that MLL1 knockdown induced G2/M phase cell-cycle arrest and apoptosis in HeLa cells.
As MLL1 knockdown induced cell-cycle arrest, we examined the effect of knockdown on various cell-cycle regulatory genes. 21, 43 We analyzed RNA from MLL1-antisense-treated and control cells by using real-time PCR and quantitative PCR (qPCR). Our results showed that MLL1 knockdown downregulated the expression of various cell-cycle regulatory genes, such as cyclin A, cyclin B and p57 (Figure 2b , qPCR data is in the right panel). Chromatin immunoprecipitation (ChIP) studies showed that MLL1 knockdown resulted in decreased histone H3K4 trimethylation and RNA polymerase II recruitment at the promoters of cyclin A, cyclin B and p57 affecting their expression ( Figure 2c ). These results demonstrated that MLL1 is a key regulator of cyclins and p-proteins and hence regulate cell-cycle progression.
Notably, cell-cycle progression is tightly regulated by sequential activation and inactivation of various cyclin-dependent kinases whose activities are regulated by cyclins. 44, 45 The cyclin D and E are required for progression through G1 phase. Cyclin A is produced in late G1 and it accumulates during S and G2 phase.
The cyclin B is typically expressed during the G2-to M-phase transition and controls passage through the M phase. 44, 45 Our results showed that knockdown of MLL1 downregulated the cyclin B expression, whereas cyclin D and E are mostly unaffected ( Figure 2b ). As cyclin B is critical for G2-to M-phase transition, downregulation of cyclin B under MLL1-knockdown environment contributed towards cell-cycle arrest at G2/M phase (Figure 2a ). We also observed that MLL1 knockdwon downregulated p57 expression. Notably, p57 is well recognized as cyclin-dependent kinase inhibitor and its inhibition increases cell proliferation. 46 Thus, the decrease in p57 upon MLL1 knockdown should increase cell proliferation, instead of observed apoptosis. However, as cyclin B and p57 are common targets of MLL1, it is likely that the effect of G2/M-phase arrest via cyclin B downregulation may have surpassed the proliferative effect of p57 downregulation under MLL1-knockdown environment. These analyses demonstrated that MLL1 is a critical factor in cell-cycle regulation and its knockdown resulted in G2/M-phase cell-cycle arrest, ultimately leading to apoptosis.
MLL1 knockdown suppressed cervical tumor growth in vivo. As MLL1 knockdown induced apoptosis in HeLa cells, we explored potential impact of MLL1 knockdown in controlling cervical tumor growth in vivo using mouse xenograft model. Prior to getting into xenograft experiments, we examined the animal toxicity of MLL1 antisense using athymic nude mouse. We injected intraperitoneally three different dozes (100, 300 and 500 mg/20 g body weight) of MLL1 antisense (MLL1-A3) and scramble antisense into 6-weekold nude mouse (three replicates each) and then monitored the health of each mouse on a daily basis for a month. Notably, similar ranges of antisense dozes are known to be effective in antineoplastic therapy. 2 Our results demonstrated that upon application of MLL1 antisense, all mice survived without loss of body weight and were grown similar to untreated control mice. As MLL1 antisense showed no significant toxicity towards mouse, we examined its efficacy towards regression of cervical cancer xenograft implanted in nude mouse. We administered MLL1 antisense intraperitoneally on athymic nude mice carrying the cervical cancer xenografts. In brief, 2 Â 10 6 human cervical cancer cells (HeLa cells in 100 ml of phosphate-buffered saline (PBS)) were injected subcutaneously (near the right back limb). Animals were examined daily for signs of tumor growth and behavior. Once the tumor size reached B30 mm 2 (2-3 weeks after injection of HeLa cells), we administered MLL1 antisense intraperitoneally (in PBS, at 4 days interval, 300 mg/20 g body weight, in three parallel replicates). To administer the antisense systemically, we injected antisense near the rear left limb of the mice, which is away from the tumor area. Control mice were injected with equal volume of the diluents (PBS) or scramble antisense alone. Over the experimental period bidimensional measurements were carried out at 2 days interval using calipers and cross-sectional area (tumor size) were plotted (Figure 3a , representative xenografts at different stages of treatments are shown in Figure 3b ). Experiments were repeated at least in three independent sets of experiments (using three replicates each time). As seen in Figures 3a and b , the tumor size increased exponentially over time in the control mice that were either treated with PBS (diluents buffer) or scramble antisense. Interestingly, application of MLL1 antisense suppressed the tumor growth completely over the period of treatment in comparison with the controls (Figures 3a and b ). Similar to MLL1 antisense (MLL1-A3), application of MLL1-A5 antisense also effectively suppressed the growth of the xenografted tumor, though it is slightly less effective (under the similar experimental condition and doses) in comparison with MLL1-A3 ( Figure 3a ). The suppression of tumor xenograft by two independent MLL1specific antisenses (MLL1-A3 and MLL1-A5) alleviates potential off-target effects of MLL1 antisenses.
To further examine histology of MLL1-antisense-treated and control tumors, we surgically removed the tumors from mice (Figure 4a ). Notably, the control tumors, which are bigger in size (Figure 4a ), were tightly attached to the host mice tissue and the mice tissue invaded to the xenografted tumor tissue heavily. In contrast, MLL1-antisense-treated tumors were loosely floating (did not attach to the mouse tissue) under the mice skin. After excision, the exterior of the control tumor xenografts was found to be reddish and densely covered with network of blood vessels, whereas the number of visible blood vessels on the surface of the MLL1-antisense-treated tumor xenografts were less and tumors appeared whitish (Figure 4a ). Dissection of tumor tissues ( Figure 4a , bottom panels) showed that in the control xenograft (left panel), tissue is transparent, homogenous and healthy with some patches of highly condensed tissue (hypoxic regions). In the MLL1-antisense-treated xenograft (bottom right panel Figure 4a ), the interior core of the tumor was semifluidic in nature and highly opaque, indicating dead tissue. Hematoxylin and eosin staining showed the presence of well-defined cellular morphologies and nuclei in the control tumor core tissue, whereas there were no defined intact cells and nuclei present in the MLL1-antisensetreated tumor tissue, indicating dead cells (Figure 4b) .
To analyze the level of MLL1 expression in both control and MLL1-antisense-treated xenografts, protein and RNA were isolated from the homogenized tumor tissue samples at different times of treatment (14 and 28 days) and analyzed by qPCR and western blotting. Application of MLL1 antisense specifically knocked down MLL1 (but not MLL2, control) in a temporal manner both at mRNA and protein levels (Figures 4c and d) . These results demonstrated that MLL1 antisense reached the xenografted tumor tissue systemically and specifically knocked down MLL1.
To investigate further, we stained the dissected tumor tissue with DAPI (that stains nucleus) and immunostained with MLL1 proteins from the control and MLL1-antisense-treated tumors were analyzed by western blotting using antibodies specific to MLL1 and MLL2 (control). (e) Immunofluorescence staining: the control and MLL1-antisense-treated mice with cervical cancer xenograft were perfused with 4% paraformaldehyde at day 28 of treatment. The tumors were excised, sectioned and subjected to immunofluorescence staining with MLL1 antibody. Nuclear counter staining was done with DAPI and analyzed under fluorescence microscope. Representative images showing the cellular morphology (differential interference contrast (DIC)), nuclear integrity (DAPI) and MLL1 expression in the control and MLL1-antisensetreated tumors are shown. (f ) TUNEL assay: paraformaldehyde-perfused tumor sections were subjected to terminal nicked end-labeling using fluorescent dUTP. In parallel, the sections were also stained with DAPI and PI. dUTP-stained green speckles represent apoptotic cells with fragmented nuclei. antibody and analyzed it under fluorescence microscope. In the control tumor, cell nuclei were normal, round to oval shaped and stained uniformly with DAPI, indicating healthy states of cells (Figure 4e ). In the MLL1-knockdown xenograft, at the core of the tumor, the cell nuclei were fragmented, indicating dead cells (Figure 4e ). The cells were smaller, spherical and highly dense ( Figure 4e ). As anticipated, our immunostaining showed higher level of MLL1 localization primarily in the cell nuclei of the control xenograft tissues (Figure 4e ). In the MLL1-antisense-treated tumor xenograft, MLL1 was localized in patches of fragmented nuclei and level of expression of the protein was relatively less compared with that of the untreated control (Figure 4e ). TUNEL assay demonstrated that in the control tumor, the core tissue is healthy as evidenced by well-defined nuclear staining (DAPI staining, top panels, Figure 4f ). However, there is extensive nuclear fragmentation and DNA damage (intense dUTP labeling) in the core of the MLL1-antisense-treated xenografted tumor tissue and cells were mostly dead (PI staining) (bottom panels, Figure 4f ). These analyses demonstrated that knockdown of MLL1 induced cell death inside xenografted tumor and resulted in disintegration of core tumor tissue resulting in suppressed tumor growth.
MLL1 knockdown suppressed the level of angiogenesis in cervical tumor xenograft. Tumor growth is critically linked with activation of the different signaling pathways. Expression of growth factors and their receptors within tumor microenvironment affect both tumor growth and angiogenesis. Hypoxia in the tumor core is a critical driving force towards enhanced tumor growth and angiogenesis. [47] [48] [49] Expression of angiogenic factors, such as CD31, is transcriptionally regulated by VEGF, which in turn is regulated by hypoxia-inducible factor-a (HIF1a). 47 Hypoxia facilitates stabilization of HIF1a by inhibiting its degradation via inhibition of ubiquitination. Under hypoxic environment, HIF1a dimerize with aryl hydrocarbon nuclear-receptor translocator (ARNT) and binds to the VEGF promoter leading to its transactivation. 47 VEGF binds to VEGF receptor localized in the endothelial cells surface, and the activated VEGF receptor transactivates angiogenic factors, such as CD31, that promote vasculogenesis. [47] [48] [49] CD31 is well known to be expressed in the endothelial cells (located in the inner layer of blood vessels), whereas VEGF, basic fibroblast growth factor and platelet-derived growth factor are expressed in the basement membranes that support the differentiation and maintenance of endothelial layers in blood vessels. [47] [48] [49] As our initial observation (Figure 4a ) showed the presence of lesser number of blood vessels in the MLL1-antisense-treated tumor in comparison with the control, we examined if knockdown of MLL1 affects the expression of HIF1a, VEGF and CD31 in the tumor xenograft. We isolated RNA from the control and antisensetreated tumor tissues and analyzed using qPCR. Our results demonstrated that upon application of MLL1 antisense, along with MLL1, expression of HIF1a, VEGF and CD31 were decreased (Figure 5a ). Chromatin immunoprecipitation (ChIP with tumor tissue) analysis showed that knockdown of MLL1 resulted in decreased level of histone H3K4 trimethylation and RNA polymerase II recruitment (as well as MLL1 recruitment) at the promoters of HIF1a, VEGF and CD31 genes (Figure 5b , qPCR data in the bottom panel). Notably, histone H3K4 trimethylation is well known to be enriched in the promoter regions of transcriptionally active genes and facilitates the recruitment of RNA polymerase II and transcription initiation. Thus, decrease in H3K4 trimethylation at the promoters of HIF1a, VEGF and CD31 genes, upon MLL1 depletion, suggests that MLL1-mediated histone methylation is crucial for expression of the above target genes. Together, these results demonstrated that MLL1 is a key regulator of HIF1a, VEGF and CD31, and hence tumor growth and angiogenesis.
Furthermore, we examined the expression of MLL1, CD31, VEGF and HIF1a using immunofluorescence and immunohistological staining. Notably, CD31 is expressed in endothelial cells of blood vessels and is used as a marker for angiogenesis. Upon immunofluorescence staining with CD31, we observed that, in the control tumor, a large number of blood vessels from tumor peripheral tissue were actively invading towards the core tumor tissue (Figure 6a , higher magnification/resolution images showing the localization of CD31 and MLL1 are shown in Supplementary  Figure S6 ). Increased vascular branching and generation of new blood vessels were also observed in the control tumor (Figure 6a , control tumor). Distinct blood vessels (CD31 staining) were also observed at the inner core of the control tumor (Figure 6b, top  panel) . The extensive network of blood-vessel formation is likely associated with high demand of oxygen supply for the rapidly growing tumor tissue. In contrast, in the MLL1-antisense-treated xenograft, there was no sign (lack of CD31 staining) of bloodvessel invasion or de novo blood-vessel formation both at the outer surface and at the tumor core and the tissues were mostly dead (Figures 6a and b, MLL1-antisense-treated) . Notably, a thin layer of live xenografted human cells (as evidenced by intense layer of DAPI staining) was observed at the exterior surface of the MLL1-antisense-treated tumor (Figure 6a , bottom panel, indicated by arrow). The existence of these resistant tumor cells in the external tumor surface might be supported by plenty of oxygen supply from the host tissue.
Interestingly, immunofluorescence staining showed that MLL1 and CD31 were highly localized in tissues along the line of blood vessel (Figure 6b , top panels and Supplementary Figure S6) . A more detailed view of MLL1 and CD31 localization, surrounding a particular blood vessel (vertical cross-section) is shown in Figure 6c . Importantly, though MLL1 and CD31 are both overexpressed along the vascular lining, they were not colocalized (Figure 6c and Supplementary Figure S6 Figure S6 ). To further confirm, the relative localization of MLL1 and CD31, we performed 3,3'-Diaminobenzidine (DAB) staining independently (Figures 6d  and e ). DAB staining also showed that MLL1 and CD31 were overexpressed along the line of blood vessels, and CD31 is localized in the inner core (endothelial cell) of the blood vessel, whereas MLL1 is localized at the outer layer of the blood vessel (basement membrane) (Figures 6d and e ). Hematoxylin and eosin staining along with CD31 and MLL1 immunostaining further confirmed that CD31 is localized in the inner core of the blood vessel, whereas MLL1 is localized towards the outer layer of the blood vessel (Figure 6f) . Notably, the basement membrane that expresses several growth factors, such as VEGF, basic fibroblast growth factor and so on, supports the differentiation and formation of endothelial layers during vascular development. Our immunofluorescence analysis also showed that VEGF is expressed in the adjacent tissue (basement membrane) expressing CD31 (endothelial cells) (Figure 6g ). Thus, our observations showing high expression of MLL1 in the basement membrane, and critical requirement of MLL1 in transcriptional regulation of VEGF and CD31, suggested that MLL1 has critical roles in vasculogenesis.
HIF1a is known to be overexpressed and enriched in the hypoxic region. 50, 51 HIF1a activates the signaling cascade that results in CD31 expression via VEGF. 52, 53 Our results demonstrated that MLL1 also regulates the expression of HIF1a, VEGF and CD31. To analyze further if MLL1 has any roles in hypoxia signaling, we examined the expression of MLL1 and HIF1a in the hypoxic regions of the tumor (control xenograft). We observed that HIF1a is overexpressed in the regions where condensed patches of opaque cell mass were distinctly visible in the control tumor, indicating the presence of hypoxic environment in those regions of tumor tissue (Figure 7a, top panels) . Interestingly, we also observed that MLL1 is overexpressed/enriched in those hypoxic regions along with HIF1a (Figure 7a, top panels) . A higherresolution image showing the colocalization of MLL1 and HIF1a in the hypoxic regions is shown in Figure 7b . The overexpression of MLL1 and HIF1a in the hypoxic region is also demonstrated by DAB staining (Figures 7c and d) . The overexpression/enrichment of MLL1 in the hypoxic environment and transcriptional regulation of HIF1a by MLL1 indicated that MLL1 is associated with hypoxia signaling within tumor microenvironment. In the MLL1-antisensetreated xenograft, as most tissue was dead, we did not observe any hypoxic regions as indicated by the absence of MLL1 and HIF1a staining (Figure 7a, bottom panels) . Additionally, we observed some networks of blood vessels surrounding the hypoxic regions where MLL1 is also overexpressed (Figure 7a , shown by arrow marks), indicating further the potential roles of MLL1 in de novo blood-vessel formation driven by hypoxia.
DISCUSSION
Our biochemical studies demonstrated that MLL1 has key roles in regulation of cell-cycle progression and cell viability. MLL1 knockdown affects various cell-cycle regulatory genes (including cyclin A, cyclin B and p57), resulting in cell-cycle arrest in G2/M phase and apoptosis in cultured cells. Notably, MLL1 is a critical histone methylase and gene regulator, and its knockdown affects expression of various genes, including crucial cell-cycle regulatory cyclin and p-proteins, that ultimately led to cell-cycle arrest and apoptosis in most cell types (both malignant and nonmalignant). However, malignant cells were relatively more sensitive to MLL1 knockdown in comparison with nonmalignant cells, this may be likely because malignant cells proliferate more rapidly than normal cells, and gene expression by MLL1 is essential for cell proliferation.
Importantly, for the first time, we demonstrated that antisensemediated MLL1 knockdown suppressed tumor growth in vivo (cervical cancer xenograft). MLL1 antisense reached the tumor systemically and specifically downregulated MLL1 expression in the tumor tissue, and that results in suppression of HIF1a, VEGF and CD31 expression affecting tumor growth and level of angiogenesis. Notably, though we observed that MLL1 antisense suppressed the growth of the xenograft, it did not lead to shrinkage in tumor volume. Tissue section analysis showed that in the MLL1-antisense-treated xenograft, most of the core tissue is dead (degraded). However, a layer of live cells is still present on the edge of tumor xenograft (external periphery of the tumor) that is attached to host (mice) tissue (see Figure 6a , shown by arrow). These cells are more resistant to death likely because they get plenty of oxygen (and nutrients) supply from host tissue and thus are not as hypoxic as the interior core tumor tissue. The presence of this intact layer of live tumor tissue at the periphery of the tumor does not allow the shrinkage of the overall tumor volume, though the interior of the existing tumor is mostly dead and degraded.
Interestingly, we found that similar to CD31, MLL1 is overexpressed along the linings of the blood vessel distinctly marking the vascular network. Though both MLL1 and CD31 are overexpressed along the vascular network, they are not colocalized. CD31 is expressed in the endothelial cells, whereas MLL1 is expressed in the neighboring outer layers of cells (basement membrane) that supports the formation and differentiation of endothelial layer during vasculogenesis. MLL1 is known to have critical roles in hematopoietic cell differentiation, and hematopoietic stem cell is linked with origin of endothelial cells. 54 Recent studies also indicate that MLL1 is critical for formation of endothelial cells. 55 Our studies showing the high expression of MLL1 in the basement membrane further support its critical roles in development of endothelial cells during angiogenesis. Furthermore, overexpression of MLL1 in the hypoxic regions of the tumor where HIF1a is overexpressed indicates a strong link between hypoxia signaling and MLL1. Overall, our studies demonstrated that MLL1 is a key factor in cell proliferation and tumor growth, and knockdown of MLL1 results in suppression of tumor growth and angiogenesis obtained from American Type Cell Culture Collection (Manassas, VA, USA), grown and maintained as described previously. 41, 42 For transfection, cells were grown up to 60% confluency in 60-mm culture plate and then transfected with MLL1-antisense oligonucleotides ( Supplementary Table S1 ) using ifect (MoleculA) transfection reagent. 41, 42 RNA was isolated and quantified from antisense-treated and control cells, reverse transcribed to cDNA and subjected to real-time PCR (qPCR) as described previously (details in Supplementary  Information) . Proteins from the antisense-treated and control cells were analyzed by western blotting using antibodies against MLL1 (Abgent, San Diego, CA, USA), MLL2, (Abgent) and b-actin (Sigma, St Louis, MO, USA).
Analyzing cell viability, morphology and cytotoxicity. The cytotoxicity of MLL1 antisenses were determined by MTT assay as described previously. 56 For analyzing effect of MLL1 antisense on cell viability and morphology, HeLa cells were grown in 60-mm culture plates and transfected with MLL1 (or scramble) antisense for 48 h, stained with trypan blue (10 min) and visualized under differential interference contrast setting of a microscope (Nikon Eclipse TE2000-U, Nikon, Tokyo, Japan).
Flow-cytometry analysis, TUNEL assay and caspase 3/7 activity assay. HeLa cells were transfected with MLL1 and scramble-antisense oligonucleotides separately for 48 h, harvested, fixed in 70% ethanol for 2 h, washed twice with PBS and stained with PI (final concentration, 0.5 mg/ml). The cells were analyzed by flow cytometry, using a Beckman Coulter (Fullerton, CA, USA) Cytomics FC500 flow-cytometry analyzer as described previously. 21 TUNEL and caspase assays were performed as described by us previously (also see the Supplementary Information). 56 
DAPI
ChIP assay
Cells were transfected with MLL1 and scramble antisense for 48 h. For ChIP assay, cells were fixed with 1% formaldehyde, washed, resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8, 1 Â protease inhibitors and 0.2 mM phenylmethylsulfonyl fluoride), sonicated until chromatin was sheared to an average DNA fragment length of 0.2-0.5 kb and subjected to ChIP assay (as described previously using different antibodies as needed. 21, 41, 42 Animal toxicity and cervical cancer xenografts
All animal experiments were carried out using the IACUC approved protocol and every care and precautions were taken to minimize the pain/ stress on the animal. Animals were hosted in the institutional (UTA) animal care facility under the supervision of trained personal. Prior to getting into the xenograft experiments, the animal toxicity of each of the antisense oligonucleotides were examined using nude mouse. Six-week-old athymic nude (nu/nu) mice (obtained from Harlan, Indianapolis, IN, USA) were used for these experiments. For the toxicity analysis, we injected intraperitoneally three different dozes (100, 300 and 500 mg/20 g body weight) of MLL1 and scramble antisense into six-week-old nude mouse (three replicates each) and then monitored the health of each mouse on a daily basis for a month. We monitored the body weight at every 4 days interval after treatment with antisense. For the xenograft experiments, 2 Â 10 6 human cervical cancer cells (HeLa cell in 100 ml of PBS) were injected subcutaneously (near the right back limb). 57, 58 Animals were examined daily for signs of tumor growth and behavior. Once the tumor size reached B32 mm 2 (2-3 weeks after injection of cells), we administered MLL1 antisense intraperitoneally (PBS solution, twice in a week, 300 mg/20 g body weight, in three parallel replicates, continued for a month). Experiments were repeated at least three times. Control mice were injected with equal volume of the diluents (PBS) or scramble antisense alone. Tumor sizes were measured every 2 days interval and bidimensional measurements were carried out using calipers and tumor cross-sectional area (tumor size) were plotted. The normal growth habit of the animals was observed and body weight of the animals was recorded over the experimental period.
Immunohistological staining and RNA and protein analysis in tumor tissue
For RNA and protein analysis, tumors were directly excised from euthanized mice, flash frozen in liquid nitrogen, homogenized and subjected to RNA (ZyGEM kit, Hamilton, New Zealand) and protein extraction that were then subjected to qPCR and western blotting.
For immunohistochemical staining, mice were sequentially perfused with cold PBS (pH 7.4), followed by 4% paraformaldehyde (in PBS), and then xenografted tumors were removed, cryoprotected in PBS containing 30% sucrose and sectioned. Immunohistochemical staining (fluorescent) of the xenografted tumor sections was done as described previously. 21, 59 In brief, sections were blocked by incubating in presence of goat serum, incubated (2h) with the respective primary antibodies (CD31, MLL1 and HIFa), washed and incubated with fluorescein isothiocyanate or rhodamine-conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA, USA). Nuclear counterstaining was performed with DAPI. Immunostained cells were mounted and observed under a fluorescence microscope. For DAB staining and immunohistological analysis, the cryoprotected xenogratfted tumor sections were incubated in blocking buffer (containing donkey serum) and then with primary antibodies specific to MLL1, CD31, HIFa and VEGF. Sections were then incubated with biotinylated donkey secondary antibody followed by avidin-biotin complexes (ABC), followed by peroxidase labeling using a DAB substrate kit (Vector Laboratories, Burlingame, CA, USA). Sections were mounted with DPX mounting solution (BDH, Atlanta, GA, USA) and examined under light microscope.
ChIP assay with tumor tissue
For ChIP, mice were sequentially perfused with cold PBS (pH 7.4), followed by 4% paraformaldehyde (in PBS), and then xenografted tumors were removed, cryoprotected in PBS containing 30% sucrose and sectioned. The tissue was homogenized and sonicated in presence of cell-lysis buffer to shear the chromatin to a fragment length of B0.2-0.5 kb. The fragmented chromatin was precleaned and then incubated with MLL1, RNA polymerase II (Abcam, Cambridge, MA, USA), H3K4 trimethyl (Upstate, Billerica, MA, USA) and b-actin antibodies overnight, and subjected to immunoprecipitation using agarose beads. The immunoprecipitated chromatin was deproteinized and PCR-amplified using promoter-specific primers (qPCR).
